MedicaidPrior AuthMedium impact
Jevtana® (cabazitaxel)
Humana·IN · Oncology, Urology·Medicaid
Effective date
Sep 1, 2025
We identified it
Jun 24, 2026
Summary
New prior authorization policy for Jevtana (cabazitaxel) intravenous solution for Indiana Medicaid patients with hormone-refractory metastatic prostate cancer. Requires specific criteria including previous docetaxel treatment and concurrent corticosteroid use, with several clinical exclusions that prevent approval.
Action Required
By September 1, 2025: Billing team must implement prior authorization requirements for Jevtana (cabazitaxel) IV solution for Indiana Medicaid patients. Verify patients meet all three criteria: hormone-refractory metastatic prostate cancer diagnosis, previous docetaxel treatment, and concurrent corticosteroid use. Check for exclusions including neutrophil count ≤1,500/mm3, hepatic impairment (bilirubin >3x ULN), and concomitant use with abiraterone or enzalutamide. Claims without prior auth will be denied.